AI Science Tracker
EN

Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

1 discovery from 2024

Discoveries

Comprehensive multi-omics analysis identifies chromatin regulator-related signatures and TFF1 as a therapeutic target in lung adenocarcinoma through a 429-combination machine learning approach

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: A 429-combination learned prognostic signature stratified lung-adenocarcinoma survival; TFF1 knockdown also reduced tumor growth in experimental models. The result is limited to the reported study population and evaluation; the source does not establish transfer to other populations or improved clinical outcomes.

Technology: Random-survival-forest and gradient-boosting prognostic models

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Random-survival-forest and gradient-boosting prognostic models
Limitation / still unknown
The study does not establish improved patient outcomes or generalization beyond the evaluated setting.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1481753/full · https://doi.org/10.3389/fimmu.2024.1481753 · https://pubmed.ncbi.nlm.nih.gov/39539551/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.